Skip to main content

Rivaroxaban Dosage

Medically reviewed by Drugs.com. Last updated on Apr 7, 2023.

Applies to the following strengths: 1 mg/mL; 2.5 mg; 15 mg; 20 mg; 10 mg; 15 mg-20 mg

Usual Adult Dose for Atrial Fibrillation

20 mg orally once a day with evening meal

Comments:


Use: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Usual Adult Dose for Deep Vein Thrombosis

15 mg orally twice a day


Comments:

Uses:

Usual Adult Dose for Pulmonary Embolism

15 mg orally twice a day


Comments:

Uses:

Usual Adult Dose for Deep Vein Thrombosis - Recurrent Event

10 mg orally once a day

Comments:


Use: For the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months

Usual Adult Dose for Pulmonary Embolism - Recurrent Event

10 mg orally once a day

Comments:


Use: For the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months

Usual Adult Dose for Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery

10 mg orally once a day

Duration of Therapy:


Comments:

Use: For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

Usual Adult Dose for Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery

10 mg orally once a day

Duration of Therapy:


Comments:

Use: For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

Usual Adult Dose for Venous Thromboembolism

10 mg orally once a day
Total duration of therapy: 31 to 39 days

Comments:


Use: For the prophylaxis of VTE and VTE related death during hospitalization and post hospital discharge in patients admitted for an acute medical illness who are at risk of thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE and not at high risk of bleeding

Usual Adult Dose for Coronary Artery Disease

2.5 mg orally twice a day

Comments:


Uses:

Usual Adult Dose for Peripheral Arterial Disease

2.5 mg orally twice a day

Comments:


Uses:

Usual Adult Dose for Cardiovascular Risk Reduction

2.5 mg orally twice a day

Comments:


Uses:

Usual Pediatric Dose for Venous Thromboembolism

Birth to Less than 18 Years:
Oral suspension:


Tablets:

Comments:

Use: For the treatment of VTE and the reduction in the risk of recurrent VTE in patients after at least 5 days of initial parenteral anticoagulant therapy

Usual Pediatric Dose for Congenital Heart Disease

2 Years or Older:
Oral suspension:


Tablets:

Comments:

Use: For thromboprophylaxis in patients with congenital heart disease who have undergone the Fontan procedure

Renal Dose Adjustments

ADULT PATIENTS:
Reduction in risk of stroke in nonvalvular atrial fibrillation:


Treatment of DVT and/or PE, reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE, prophylaxis of DVT after hip or knee replacement surgery, prophylaxis of VTE in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding:

PEDIATRIC PATIENTS:
Younger Than 1 Year:

Reference values of serum creatinine in patients younger than 1 year (Age: 97.5th Percentile of Creatinine):

1 Year or Older:

Comments:
ADULT PATIENTS:
PEDIATRIC PATIENTS:

Liver Dose Adjustments

Adult patients:


Pediatric patients:

Comments:

Dose Adjustments

Switching To and From This Drug:


Discontinuation for Surgery and Other Interventions:

Precautions

US BOXED WARNINGS:


CONTRAINDICATIONS:

Safety and efficacy of the 2.5 mg tablets have not been established in patients younger than 18 years; this formulation is not recommended for use in these patients.

Consult WARNINGS section for additional precautions.

Dialysis

Adult Patients:
Nonvalvular atrial fibrillation:


Treatment of DVT, PE, and reduction in the risk of recurrence of DVT and PE; prophylaxis of DVT after hip or knee replacement surgery; prophylaxis of VTE in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding:

Reduction of risk of major cardiovascular event in patients with CAD and reduction of risk of major thrombotic vascular events in patients with PAD, including patients after recent lower extremity revascularization due to symptomatic PAD:

Comments:

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques (oral suspension):

General:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.